Greggs facing thinner sausage roll demand due to rise of weightloss drugs

Jefferies downgraded Greggs to 'hold' from 'buy', warning that the rapid uptake of GLP‑1 weight‑loss drugs (tirzepatide and semaglutide), now used by roughly 7% of UK adults, is a structural headwind to high‑frequency purchases of savoury, high‑calorie items; management has already reported like‑for‑like sales weakening since mid‑2024 and negative customer volumes. The broker trimmed sales growth and margin assumptions and lowered its price target, and the shares fell 4.9% to 1,599p; Jefferies expects a muted 2026 for non‑food retail and highlights AO World, Wickes and Moonpig as preferred names.

Analysis

Market structure: The rapid adoption of GLP‑1 drugs (≈7% of UK adults) shifts demand away from high‑frequency, high‑calorie impulse purchases—clear losers are quick‑serve bakery/snack chains (eg Greggs, -4.9% move) and suppliers dependent on repeat footfall; winners are durable‑goods and home‑improvement retailers (Wickes) and membership/online ecosystems (AO) that benefit from reduced eating‑out frequency. Pricing power for impulse sellers will weaken as frequency, not basket size, falls; ingredient commodity exposure is muted but real estate and labour leverage become more painful as volumes drop.

Risk assessment: Tail risks include accelerated GLP‑1 uptake to >12% adult penetration within 12–24 months producing a 10–20% permanent traffic loss, or conversely regulatory limits on prescribing that restore volumes quickly (30–90 days news catalyst). Hidden dependencies: high‑frequency customers are skewed by age/income—if substitutes (low‑calorie menu) capture >30% of GLP‑1 users, impact halves; lease maturities and franchise roll‑outs create lumpy near‑term cashflow stress. Key catalysts: quarterly LFL footfall data, NHS prescribing guidance, and competitor case studies over next 2–6 quarters.

Trade implications: Short selective exposure to Greggs (LSE: GRG) and hedge with longs in Wicks (LSE: WIX) and AO (LSE: AO) — initial sizing 2–3% portfolio each, horizon 3–12 months. Use options to limit capital: buy 6‑month GRG put spreads (eg buy 1400p / sell 1000p) or sell covered calls on long WIX to enhance yield; increase short if LFL volumes fall >5% YoY for two consecutive quarters. Rotate 2–5% from casual‑dining/impulse retailers into home improvement and high‑margin online retail stocks.

Contrarian angle: Consensus treats GLP‑1 impact as linear and permanent; but adoption is cohorted and reversible via new product positioning (low‑calorie lines), loyalty and pricing promotions. Historical parallels (smoking declines, sugary drinks reformulations) show incumbents can recoup 30–50% of lost occasions through SKU innovation within 12–24 months—monitor product launches and 90‑day footfall inflection before enlarging shorts beyond 5% exposure.

Key Decisions for Investors

• Establish a 2–3% portfolio short in Greggs (LSE: GRG) via equity or buy 6‑month put spread (buy 1400p / sell 1000p) targeting ~20% downside (~1,280p) over 3–9 months; set stop‑loss at +15% from entry and increase to 4–5% if LFL customer volumes decline >5% YoY for two consecutive quarters.
• Initiate 2–3% longs in Wickes (LSE: WIX) and AO World (LSE: AO) to pair with the Greggs short (long WIX/AO, short GRG) — expectation: 12–24 month outperformance of 15–25% as consumers reallocate spend to home improvement/online ecosystems; harvest if stock outperforms the short by >10% in 6 months.
• Implement options collar on WIX long positions (buy stock, sell 6–9 month 10% OTM calls) to monetize immediate carry while retaining upside; simultaneously buy 6‑month put protection on GRG instead of naked short to cap tail risk.
• Reduce aggregate exposure to UK casual‑dining/impulse food basket by 3–5% and redeploy into consumer discretionary names with structural demand (WIX, AO) over the next 30–90 days; reassess after next two quarterly trading updates.
• Monitor specific catalysts for 30–90 days: NHS/UK prescribing guidance, GLP‑1 penetration moving above 10%, and peer LFL footfall data. If any catalyst reverses (eg prescribing curbs or Greggs LFL recover >1% sequentially), close or materially pare shorts within 10 trading days.